Cooperative Agreement UG1CA189823

Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Alliance Nctn Foundation a $4.58 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the long-term follow-up of the Comparison of an Operation to Monitoring, with Option of Endocrine Therapy (COMET) Study. The award, effective July 1, 2026 through June 30, 2030, funds continued data collection, analysis, and integration services to support this clinical research initiative....

The Seattle Cancer Care Alliance will receive $1,056,000 through a three-year Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a functional genomics approach to identify renal cell carcinoma antigens targeted by T cells in the tumor microenvironment. Through September 2024, the Alliance will apply genomic techniques to investigate medical solutions for renal cell carcinoma on the battlefield and...

Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $962,104 to the Research Institute at Nationwide Children's Hospital, effective July 3, 2025 through June 30, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports the development and clinical testing of novel therapeutic approaches targeting mutant-MYOD1 driven rhabdomyosarcoma (RMS), the most common soft tissue cancer in the pediatric population. The...

COOPERATIVE AGREEMENT SUMMARY The University of Pennsylvania's Abramson Cancer Center (ACC) received a $368,701 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 20, 2026, through February 29, 2032. This award supports the ACC's Lead Academic Participating Sites (LAPS) initiative, which serves as a centralized hub for the NCI's National Clinical Trials Network (NCTN). Under the direction of Principal...

Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $2.56 million Cooperative Agreement to The University of Texas MD Anderson Cancer Center under the Cancer Centers Support Grants program (CFDA 93.397) on August 22, 2025, with a completion date of July 31, 2030. This award funds a Lymphoma Outcomes Specialized Program of Research Excellence (SPORE) focused on addressing health disparities in lymphoma outcomes among African American and Hispanic patients. The...

Federal Cooperative Agreement Summary The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. received a $57.99 million Cooperative Agreement from the Uniformed Services University of the Health Sciences (USUHS) under the Uniformed Services University Medical Research Projects program (CFDA 12.750) for the Murtha Cancer Center Translational Clinical Research: Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) initiative and Framingham Core. Awarded on...

Federal Cooperative Agreement Summary The University of Alabama at Birmingham received a $318,167 Cooperative Agreement from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion targeted for August 31, 2032. The award funds the WARRIORS Trial (Women's Aneurysm Research: Repair Immediately or Routine Surveillance), an international randomized controlled trial designed to establish...

Federal Cooperative Agreement Summary The Air Force Research Laboratory (AFRL) awarded a $2.5M Cooperative Agreement to the University of Maryland, Baltimore on May 12, 2025, under the Air Force Defense Research Sciences Program (CFDA 12.800) to support research on the generation of low titer Type O whole blood through adsorption of anti-A and -B isoagglutinins. The two-year project, with an ultimate completion date of May 12, 2027, addresses critical blood supply challenges by developing...

Federal Cooperative Agreement Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Cooperative Agreement valued at $609,683 to the University of North Carolina at Chapel Hill, effective September 1, 2025, through May 31, 2030, to establish and operate the Rare Bronchiectatic Diseases Consortium (RBDC). This award supports research under the Cardiovascular Diseases Research program (CFDA 93.837) to accelerate therapeutic development for four rare bronchiectatic diseases:...

Cooperative Agreement Summary Wake Forest University Health Sciences received a $248,194 Cooperative Agreement from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded May 1, 2025, with a completion date of April 30, 2028. This award supports a preparatory phase for a multisite clinical trial focused on improving collaboration between radiation oncologists and radiologists in cancer treatment planning and surveillance. The primary...